Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $7
Balanced Hold Recommendation for Adaptive Biotechnologies Amid Positive Performance and External Challenges
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Scotiabank Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $10
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
Adaptive Biotechnologies Is Maintained at Overweight by Piper Sandler